NasdaqGS:VIVO

Stock Analysis Report

Executive Summary

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.

Snowflake

Fundamentals

Adequate balance sheet and fair value.


Similar Companies

Share Price & News

How has Meridian Bioscience's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.2%

NasdaqGS:VIVO

0.8%

US Medical Equipment

1.1%

US Market


1 Year Return

-35.5%

NasdaqGS:VIVO

9.6%

US Medical Equipment

2.1%

US Market

VIVO underperformed the Medical Equipment industry which returned 9.1% over the past year.

VIVO underperformed the Market in United States of America which returned 2% over the past year.


Share holder returns

VIVOIndustryMarket
7 Day5.2%0.8%1.1%
30 Day-1.2%0.2%3.7%
90 Day-15.3%2.7%2.3%
1 Year-34.6%-35.5%10.5%9.6%4.4%2.1%
3 Year-43.5%-48.2%69.5%64.3%47.0%37.4%
5 Year-33.7%-44.3%132.5%105.9%61.6%43.8%

Price Volatility Vs. Market

How volatile is Meridian Bioscience's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Meridian Bioscience undervalued based on future cash flows and its price relative to the stock market?

16.51x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Meridian Bioscience's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Meridian Bioscience's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Meridian Bioscience is good value based on earnings compared to the US Medical Equipment industry average.

Meridian Bioscience is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Meridian Bioscience earnings are not expected to grow next year, we can't assess if its growth is good value.


Price Based on Value of Assets

Meridian Bioscience is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Meridian Bioscience expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

-0.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Meridian Bioscience's revenue is expected to grow by 1.8% yearly, however this is not considered high growth (20% yearly).

Meridian Bioscience's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.

Meridian Bioscience's revenue growth is positive but not above the United States of America market average.

Meridian Bioscience's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Meridian Bioscience's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Meridian Bioscience is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Meridian Bioscience performed over the past 5 years?

-10.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Meridian Bioscience's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

Meridian Bioscience's 1-year earnings growth exceeds its 5-year average (6.5% vs -10.7%)

Meridian Bioscience's earnings growth has not exceeded the US Medical Equipment industry average in the past year (6.5% vs 28.9%).


Return on Equity

Meridian Bioscience has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Meridian Bioscience used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Meridian Bioscience's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Meridian Bioscience's financial position?


Financial Position Analysis

Meridian Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Meridian Bioscience's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Meridian Bioscience's level of debt (40.2%) compared to net worth is high (greater than 40%).

Unable to establish if Meridian Bioscience's debt level has increased without past 5-year debt data.

Debt is well covered by operating cash flow (52.2%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 51.6x coverage).


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 1.8x debt.


Next Steps

Dividend

What is Meridian Bioscience's current dividend yield, its reliability and sustainability?

0.63%

Expected Dividend Yield


Dividend Yield and Payments Analysis

Unable to evaluate Meridian Bioscience's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Meridian Bioscience's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Meridian Bioscience has not reported any payouts.

Unable to verify if Meridian Bioscience's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Meridian Bioscience has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Meridian Bioscience's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Meridian Bioscience's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Jack Kenny (50yo)

1.9yrs

Tenure

US$1,872,166

Compensation

Mr. John P. Kenny, also known as Jack, has been the Chief Executive Officer of Meridian Bioscience, Inc. since October 9, 2017 and its Executive Vice President of the Diagnostics Business Unit since March  ...


CEO Compensation Analysis

Jack's remuneration is about average for companies of similar size in United States of America.

Insufficient data for Jack to compare compensation growth.


Management Age and Tenure

0.8yrs

Average Tenure

56yo

Average Age

The average tenure for the Meridian Bioscience management team is less than 2 years, this suggests a new team.


Board Age and Tenure

2.7yrs

Average Tenure

65yo

Average Age

The average tenure for the Meridian Bioscience board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$22,51623 May 19
John Rice
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares2,000
Max PriceUS$11.26
BuyUS$56,85520 May 19
James Anderson
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares5,000
Max PriceUS$11.37
BuyUS$57,01513 May 19
David Phillips
EntityIndividual
Role
Chairman of the Board
Chairman of the Board & Lead Independent Director
Shares5,000
Max PriceUS$11.40
BuyUS$229,74409 May 19
John Kenny
EntityIndividual
Role
Chief Executive Officer
President
Shares20,000
Max PriceUS$11.49
BuyUS$9,34425 Feb 19
Dwight Ellingwood
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares566
Max PriceUS$19.62
SellUS$681,22914 Nov 18
Lawrence Baldini
EntityIndividual
Shares35,101
Max PriceUS$19.55

Ownership Breakdown


Management Team

  • Susan Rolih (70yo)

    Consultant

    • Tenure: 0.8yrs
    • Compensation: US$626.75k
  • Melissa Lueke (56yo)

    Consultant

    • Tenure: 0.7yrs
    • Compensation: US$629.27k
  • Bryan Baldasare

    Interim CFO

    • Tenure: 0.3yrs
  • Lourdes Weltzien

    Executive Vice President of Life Science Business Unit

    • Tenure: 6yrs
  • Jack Kenny (50yo)

    President

    • Tenure: 1.9yrs
    • Compensation: US$1.87m
  • Melissa McCarey

    Vice President of Global Human Resources

    • Tenure: 0yrs

Board Members

  • John Rice (69yo)

    Independent Director

    • Tenure: 2.1yrs
    • Compensation: US$92.54k
  • John McIlwraith (60yo)

    Independent Director

    • Tenure: 4.1yrs
    • Compensation: US$93.79k
  • David Phillips (81yo)

    Chairman of the Board & Lead Independent Director

    • Tenure: 1yrs
    • Compensation: US$128.79k
  • James Anderson (77yo)

    Independent Director

    • Tenure: 10.2yrs
    • Compensation: US$110.79k
  • Felicia Williams (53yo)

    Director

    • Tenure: 1yrs
    • Compensation: US$41.11k
  • Dee Ellingwood (67yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: US$95.79k
  • Catherine Sazdanoff (63yo)

    Independent Director

    • Tenure: 4.1yrs
    • Compensation: US$92.79k
  • Jack Kenny (50yo)

    President

    • Tenure: 1.9yrs
    • Compensation: US$1.87m
  • Dave Phillips

    • Tenure: 0.8yrs

Company Information

Meridian Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Meridian Bioscience, Inc.
  • Ticker: VIVO
  • Exchange: NasdaqGS
  • Founded: 1976
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$426.688m
  • Shares outstanding: 42.71m
  • Website: https://www.meridianbioscience.com

Number of Employees


Location

  • Meridian Bioscience, Inc.
  • 3471 River Hills Drive
  • Cincinnati
  • Ohio
  • 45244
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VIVONasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJul 1986
MR4DB (Deutsche Boerse AG)YesCommon SharesDEEURJul 1986
0K0KLSE (London Stock Exchange)YesCommon SharesGBUSDJul 1986

Biography

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 23:38
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.